Entest Announces Promising Results From ImenVax(TM) Canine Cancer Vaccine Safety Study
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 07/28/11 -- Data obtained from Entest BioMedical Inc.'s (OTCQB: ENTB) (PINKSHEETS: ENTB) ImenVax™ Safety Study indicates no major side effects or safety issues resulting from treatment. ImenVax™ is Entest's immuno-therapeutic cancer vaccine for the treatment of oral melanoma in dogs. The treatment has been successfully tested for safety on the first two dogs of a ten dog safety study.
Dr. Steve Josephs noted, "Our first dog in the study had no side effects to ImenVax™ or the implantation device. The second dog had minor irritation at the implantation site which was easily treated. This is a very significant step towards having a therapy for use by veterinarians in treating dogs with oral melanoma."
Entest Chairman & CEO David Koos commented, "In both of these dogs there appears strong anecdotal evidence that Entest's immuno-therapeutic cancer vaccine for canines is safe. These initial results give us confidence that once testing is completed on additional dogs the Company will be able to demonstrate more than just anecdotal evidence of ImenVaxsafety in usage. As a person who has two basset hounds potentially at risk for developing cancer in the future, I am excited by our progress to this point. I anticipate Entest making this vaccine available in the future to better the lives of our pets."
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Entest BioMedical Inc.
David R. Koos
Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.07.2011 - 12:00 Uhr
Sprache: Deutsch
News-ID 38749
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Livestock
Diese Pressemitteilung wurde bisher 275 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Entest Announces Promising Results From ImenVax(TM) Canine Cancer Vaccine Safety Study"
steht unter der journalistisch-redaktionellen Verantwortung von
Entest BioMedical Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
